Publications by authors named "G Scapin"
Article Synopsis
- Cytokines are key players in immune responses and are being targeted for treatments in autoimmune diseases and cancer, but their glycosylation (the addition of sugar molecules) is often overlooked.
- Many therapeutic cytokines are produced in different host cells, which can lead to variations in their glycosylation patterns compared to naturally occurring human cytokines, potentially affecting their immune functions.
- By studying the glycosylation of specific human cytokines, researchers aim to understand its effects on future cytokine therapies, which is crucial for improving their safety, effectiveness, and overall therapeutic potential.
Article Synopsis
- The study focuses on developing new sulfone analogues of known metallo-β-lactamase inhibitors (MBLis) and their antibacterial effectiveness.
- The new compounds showed greater effectiveness in killing gram-negative bacteria when paired with antibiotics imipenem and relebactam.
- Improved antibacterial activity is linked to stronger enzyme-inhibitor interactions and decreased bacterial cell efflux, as shown by experiments with different strains of Pseudomonas aeruginosa.
Article Synopsis
- A multidrug-resistant Gram-negative bacterium is causing serious infections and poses a growing health threat, making new treatment options essential.
- Researchers are focusing on inhibiting the MsbA transporter, which is crucial for the bacterium's survival.
- They optimized a compound known as cerastecin D, which showed promising antibacterial activity and effectiveness in mouse models for treating infections.
PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation has emerged as a promising approach to drug challenging targets including phosphatases. We developed potent PTPN2/N1 dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) which facilitate efficient complex assembly with E3 ubiquitin ligase CRL4, and mediate potent PTPN2/N1 degradation in cells and mice.
View Article and Find Full Text PDFPneumococcal conjugate vaccines (PCV) typically consist of capsular polysaccharides from different S. pneumoniae serotypes which are covalently attached to carrier protein. A well-established process to manufacture PCV is through activating polysaccharide by oxidation of vicinal diols to aldehydes, followed by protein conjugation via reductive amination.
View Article and Find Full Text PDF